Literature DB >> 17878338

Intercellular transfer of carcinoembryonic antigen from tumor cells to NK cells.

Noam Stern-Ginossar1, Shlomo Nedvetzki, Gal Markel, Roi Gazit, Gili Betser-Cohen, Hagit Achdout, Memet Aker, Richard S Blumberg, Daniel M Davis, Ben Appelmelk, Ofer Mandelboim.   

Abstract

The inhibition of NK cell killing is mainly mediated via the interaction of NK inhibitory receptors with MHC class I proteins. In addition, we have previously demonstrated that NK cells are inhibited in a class I MHC-independent manner via homophilic carcinoembryonic Ag (CEA) cell adhesion molecules (CEACAM1)-CEACAM1 and heterophilic CEACAM1-CEA interactions. However, the cross-talk between immune effector cells and their target cells is not limited to cell interactions per se, but also involves a specific exchange of proteins. The reasons for these molecular exchanges and the functional outcome of this phenomenon are still mostly unknown. In this study, we show that NK cells rapidly and specifically acquire CEA molecules from target cells. We evaluated the role of cytotoxicity in the acquisition of CEA and demonstrated it to be mostly killing independent. We further demonstrate that CEA transfer requires a specific interaction with an unknown putative NK cell receptor and that carbohydrates are probably involved in CEA recognition and acquisition by NK cells. Functionally, the killing of bulk NK cultures was inhibited by CEA-expressing cells, suggesting that this putative receptor is an inhibitory receptor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17878338     DOI: 10.4049/jimmunol.179.7.4424

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive T cells.

Authors:  Galit Eisenberg; Ronny Uzana; Aviad Pato; Shoshana Frankenburg; Sharon Merims; Eitan Yefenof; Soldano Ferrone; Tamar Peretz; Arthur Machlenkin; Michal Lotem
Journal:  J Immunol       Date:  2013-04-26       Impact factor: 5.422

2.  Cytotoxic Activity of Peripheral Blood Mononuclear Leukocytes, Activated by Interleukin-2/β-Cyclodextrin Nanocomposition against Androgen Receptor-Negative Prostate Cancers.

Authors:  Natalia Yu Anisimova; Andrey V Sosnov; Nadezhda E Ustyuzhanina; Gianfranco Baronzio; Mikhail V Kiselevsky
Journal:  ISRN Oncol       Date:  2011-08-17

3.  Senescent cells communicate via intercellular protein transfer.

Authors:  Anat Biran; Meirav Perelmutter; Hilah Gal; Dominick G A Burton; Yossi Ovadya; Ezra Vadai; Tamar Geiger; Valery Krizhanovsky
Journal:  Genes Dev       Date:  2015-04-08       Impact factor: 11.361

Review 4.  CEACAM1 as a multi-purpose target for cancer immunotherapy.

Authors:  Matthew Dankner; Scott D Gray-Owen; Yu-Hwa Huang; Richard S Blumberg; Nicole Beauchemin
Journal:  Oncoimmunology       Date:  2017-05-16       Impact factor: 8.110

Review 5.  Intercellular transfer of HLA-G: its potential in cancer immunology.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Clin Transl Immunology       Date:  2019-08-30

6.  Senescent cells and macrophages: key players for regeneration?

Authors:  Sonia S Elder; Elaine Emmerson
Journal:  Open Biol       Date:  2020-12-23       Impact factor: 6.411

7.  When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer.

Authors:  Mohamed S Hasim; Marie Marotel; Jonathan J Hodgins; Elisabetta Vulpis; Olivia J Makinson; Sara Asif; Han-Yun Shih; Amit K Scheer; Olivia MacMillan; Felipe G Alonso; Kelly P Burke; David P Cook; Rui Li; Maria Teresa Petrucci; Angela Santoni; Padraic G Fallon; Arlene H Sharpe; Giuseppe Sciumè; André Veillette; Alessandra Zingoni; Douglas A Gray; Arleigh McCurdy; Michele Ardolino
Journal:  Sci Adv       Date:  2022-04-13       Impact factor: 14.957

Review 8.  Antigen transfer and its effect on vaccine-induced immune amplification and tolerance.

Authors:  Yingying Shi; Yichao Lu; Jian You
Journal:  Theranostics       Date:  2022-08-01       Impact factor: 11.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.